CoChat
Sign Up
Cited by 449

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Developing MicroRNA Therapeutics

van Rooij, Eva, Purcell, Angela L., Levin, Arthur A.·2012·Circulation Research
DOI 10.1161/circresaha.111.247916
Open this paper in CoChat — free account

Abstract

Rarely a new research area has gotten such an overwhelming amount of attention as have microRNAs. Although several basic questions regarding their biological principles still remain to be answered, many specific characteristics of microRNAs in combination with compelling therapeutic efficacy data and a clear involvement in human disease have triggered the biotechnology community to start exploring the possibilities of viewing microRNAs as therapeutic entities. This review serves to provide some general insight into some of the current microRNAs targets, how one goes from the initial bench discovery to actually developing a therapeutically useful modality, and will briefly summarize the current patent landscape and the companies that have started to explore microRNAs as the next drug target.

Overview

Integrity signals

Registry

Crossref · 10.1161/circresaha.111.247916

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 42

  1. 10.1038/35040556 · DOI
  2. 10.1161/CIRCULATIONAHA.109.889048 · DOI
  3. 10.1016/j.cell.2009.04.021 · DOI · Paper page
  4. 10.1016/S0167-4781(99)00138-4 · DOI
  5. 10.2174/156802607780487713 · DOI
  6. 10.1517/14712598.8.1.59 · DOI
  7. 10.1038/sj.gt.3302654 · DOI
  8. 10.1161/circresaha.110.227496 · DOI
  9. 10.1016/j.chom.2008.05.013 · DOI
  10. 10.1126/science.1113329 · DOI
  11. 10.1093/nar/gkm024 · DOI
  12. 10.1038/nature06783 · DOI · Paper page
  13. 10.1093/nar/gkm1113 · DOI
  14. 10.1126/science.1178178 · DOI · Paper page
  15. 10.1126/science.1139089 · DOI
  16. 10.1161/CIRCULATIONAHA.111.030932 · DOI
  17. 10.1126/science.1141229 · DOI
  18. 10.1093/nar/gkp577 · DOI
  19. 10.1172/JCI43604 · DOI
  20. 10.1084/jem.20100035 · DOI · Paper page
  21. 10.1152/ajprenal.00273.2011 · DOI
  22. 10.1681/ASN.2010111168 · DOI
  23. 10.1126/science.1174381 · DOI
  24. 10.1126/science.1189862 · DOI · Paper page
  25. 10.1038/nature10486 · DOI · Paper page
  26. 10.1101/gad.1942810 · DOI
  27. 10.1084/jem.20100458 · DOI · Paper page
  28. 10.1101/gad.1942110 · DOI
  29. 10.1161/circresaha.111.248880 · DOI
  30. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E. Inhibition of mir-15 protects against cardiac ischemic injury [epub ahead of print Nov. 3]. Circ Res. 2011.
  31. 10.1016/j.ymgme.2010.07.016 · DOI · Paper page
  32. 10.1016/j.ymgme.2007.03.011 · DOI · Paper page
  33. Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs. 2001;2:562–573.
  34. 10.1016/S0167-4781(99)00140-2 · DOI · Paper page
  35. 10.1161/circulationaha.111.030932 · DOI
  36. 10.1089/oli.1.2000.10.35 · DOI
  37. 10.1261/rna.1326809 · DOI
  38. 10.1021/bi002396x · DOI
  39. 10.1016/S1567-5769(02)00142-X · DOI
  40. Koch T, Oerum H. Locked nucleic acid. In: , Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press; 2008.
  41. Lima W, Wu H, Crooke ST. The RNAse H mechanism. In: , Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press; 2007.
  42. Monia BP, Yu RZ, Lima W, Siwkowski A. Optimization of second generation antisense drugs: going beyond generation 2.0. In: , Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press; 2007.

Cited by

Sorted by citations

Metadata

Authors
van Rooij, E., Purcell, A. L., & Levin, A. A.
Affiliations
From miRagen Therapeutics, Inc, Boulder, CO (E.v.R.); Cooley LLP, Washington, DC (A.L.P.); and Santaris Pharma A/S, San Diego, CA (A.A.L.).
Venue
Circulation Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-02-03
Volume
110
Issue
3
Pages
496-507
ISSN
  • 0009-7330
  • 1524-4571
DOI
10.1161/circresaha.111.247916
Cited by
449
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review